Rein Therapeutics
RNTX
20 hedge funds and large institutions have $4.84M invested in Rein Therapeutics in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 14 closing their positions.
0.05% less ownership
Funds ownership: 0.35% → 0.3% (-0.05%)
26% less funds holding
Funds holding: 27 → 20 (-7)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
43% less capital invested
Capital invested by funds: $8.49M → $4.84M (-$3.65M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$595K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$360K |
| 3 |
ECM
Element Capital Management
New York
|
+$165K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$147K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$73.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.24M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$615K |
| 3 |
State Street
Boston,
Massachusetts
|
-$309K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$147K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$145K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| – | -$9K | -57 | Closed |
|
27
JP Morgan Chase
New York
| – | -$9K | -54 | Closed |
|
28
New York State Common Retirement Fund
Albany,
New York
| – | -$8K | -50 | Closed |
|
29
Citigroup
New York
| – | -$8K | -49 | Closed |
|
30
Legal & General Group
London,
United Kingdom
| – | -$7K | -44 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | -$7K | -42 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$2.6K | -23 | -88% |
|
|
AIP
33
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$3K | -22 | Closed |
|
34
UBS Group
Zurich,
Switzerland
| – | +$340 | +3 | New |
|
RNTX Hedge Fund Activity: Q2 2018 in Review
20 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2018, worth a combined $4.84M — down 43% from $8.49M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RNTX and 7 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, adding an estimated $595K. The largest seller was BlackRock, cutting an estimated $1.24M.
- 20 institutional investors held Rein Therapeutics (RNTX) as of Q2 2018, down from 27 in Q1 2018.
- Funds reported $4.84M of Rein Therapeutics stock for Q2 2018, down 43% quarter-over-quarter.
- 7 funds opened new Rein Therapeutics positions in Q2 2018 and 14 closed out, a net change of -7 holders.
- The largest Rein Therapeutics buyer in Q2 2018 was Millennium Management, an estimated $595K added.
- The largest Rein Therapeutics seller in Q2 2018 was BlackRock, an estimated $1.24M sold.
Based on aggregated 13F filings for Q2 2018.